CYTOO transforms drug discovery through advanced micropatterned platforms that deliver highly physiological cell models, generating structural, functional, and metabolic readouts while enhancing AI-driven image analysis.

Within a portfolio of clinically relevant models, CYTOO’s flagship MyoScreen™ platform addresses inherited and acquired muscle disorders. Emerging models target obesity-related metabolic dysfunction, including myosteatosis and insulin resistance.

From high-throughput screening to GMP-grade potency assays, CYTOO has supported 60+ drug development programs, advancing therapies via standardized services, custom development, and strategic partnerships.

The company has a very strong expertise in neuro-muscular diseases, also other genetic disorders and metabolic disorders (muscle weakness and waste, obesity, diabetes).

The mission of CYTOO is to help advancing therapeutic candidates to the clinics leveraging its unique technology platform, from target identification, primary and secondary drug screening, up to the development of GMP-compliant potency assays for batch release.

Examples of targeted diseases:
Duchenne Muscular Dystrophy (DMD), Myotonic Dystrophy (DM1, DM2), Facioscapulohumeral Muscular Dystrophy (FSHD), Glycogen Storage Diseases (Pompe Disease), Mitochondrial Disorders (PMM – Primary Mitochondrial Myopathies), Metabolic Disorders (Sarcopenia, Diabetes, Obesity…)